Quality environment can be achieved. As analytical technologies continue to evolve, both
the biotechnology industry and the regulatory authorities will need to continuously develop
concepts and strategies to address how new technologies impact the way in which the
Quality by Design principles inherent in the analytical lifecycle approach are applied to the
development of biopharmaceutical products. The basic concepts are described in ICH
guidelines Q8, Q9 and Q10 (ICH 2005; ICH 2008).